B7家族在急性髓性白血病中的表达及免疫治疗研究进展  

Research progress on the expression and immunotherapy of B7 family in acute myeloid leukemia

作　　者：侯勇哲 张琴[1] 吴涛[2] 陈雅洁 游静茹 杨璐 张杉杉[1,2] 白海 HOU Yongzhe;ZHANG Qin;WU Tao;CHEN Yajie;YOU Jingru;YANG Lu;ZHANG Shanshan;BAI Hai(Gansu University of Traditional Chinese Medicine,First Clinical Medical College,Gansu Lanzhou 730030,China;Hematological Disease Center of PLA,the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,Gansu Lanzhou 730050,China)

机构地区：[1]甘肃中医药大学第一临床医学院,甘肃兰州730030 [2]中国人民解放军联勤保障部队第940医院全军血液病中心,甘肃兰州730050

出　　处：《现代肿瘤医学》2023年第22期4262-4267,共6页Journal of Modern Oncology

基　　金：甘肃省白血病临床医学研究中心资助(编号:21JR7RA015)。

摘　　要：急性髓性白血病(AML)是一种克隆性造血干细胞疾病,可重塑骨髓微环境从而促进肿瘤复发和耐药形成。B7家族分子在多种肿瘤组织中异常表达,且B7家族分子通过免疫和非免疫途径影响免疫反应和肿瘤进展,是潜在的治疗靶点。然而,B7分子在AML中的表达特征和治疗价值仍不清楚。本文将从B7家族分子的特性、在AML中的表达模式及意义作一综述,以期B7分子在AML免疫治疗中发挥重要作用。Acute myeloid leukemia(AML) is a clonal hematopoietic stem cell disorder that has the ability to reshape the bone marrow microenvironment and promote medication resistance and tumor recurrence.B7 family molecules are abnormally expressed in a range of tumor tissues,and they have an effect on immune response and tumor progression via immunological and non-immune pathways,making them prospective therapeutic targets.However,the expression characteristics and therapeutic value of B7 moleculesin AML are still unclear.This review analyzes the features of B7 family molecules,expression pattern and significance in AML,with the aspiration that B7 molecules will play a prominent role in AML immunotherapy.

关 键 词：B7家族 急性髓性白血病 免疫应答 程序性死亡受体配体-1 

分 类 号：R733.71[医药卫生—肿瘤]